Patents Assigned to XIAMEN BIOTIME BIOTECHNOLOGY CO., LTD.
  • Highly active CSF1R inhibitor compound
    Patent number: 11591328
    Abstract: The present invention relates to a CSF1R inhibitor, and in particular to a highly active CSF1R inhibitor compound having the structure of formula (I). Said compound of the present invention has high inhibitory activity on CSF1R.
    Type: Grant
    Filed: May 24, 2019
    Date of Patent: February 28, 2023
    Assignee: XIAMEN BIOTIME BIOTECHNOLOGY CO., LTD.
    Inventors: Shifeng Liu, Zhiyong Yu, Wei Pang, Ji Wang, Peng Chen
  • ADENOSINE RECEPTOR ANTAGONIST
    Publication number: 20220339160
    Abstract: A compound represented by formula (I) and a pharmaceutical composition thereof. The compound represented by formula (I) may be used as an adenosine receptor inhibitor, especially as an A2A and/or A2B inhibitor, for example, the compound may be used to prevent or treat diseases related to A2A and/or A2B activity or expression.
    Type: Application
    Filed: July 29, 2020
    Publication date: October 27, 2022
    Applicant: XIAMEN BIOTIME BIOTECHNOLOGY CO., LTD.
    Inventors: Zhiyong YU, Shifeng LIU, Meng ZHAO, Gang LI, Yongqiang SHI, Meng LV
  • ADENOSINE RECEPTOR ANTAGONIST
    Publication number: 20220267350
    Abstract: A compound represented by formula (I) and a pharmaceutical composition thereof. The compound represented by formula (I) can be used as an adenosine receptor inhibitor, in particular, A2A and/or A2B inhibitors, for example, can be used for preventing or treating diseases related to A2A and/or A2B activity or expression level.
    Type: Application
    Filed: July 29, 2020
    Publication date: August 25, 2022
    Applicant: XIAMEN BIOTIME BIOTECHNOLOGY CO., LTD.
    Inventors: Zhiyong YU, Shifeng LIU, Yongqiang SHI